Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients
A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients
Sponsor: Changzhou No.2 People's Hospital
A PHASE3 clinical study on Acute T-Lymphocytic Leukemia and Induction Chemotherapy, this trial is ongoing. The trial is conducted by Changzhou No.2 People's Hospital and has accumulated 5 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Feb 2024 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2024 [monthly]
Recruiting PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE3
First recorded
Jan 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Changzhou No.2 People's Hospital
- Henan Cancer Hospital
- Shandong Provincial Hospital
- Shenzhen People's Hospital
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- The First Affiliated Hospital of Anhui Medical University
- The First Affiliated Hospital of Soochow University
- The Second People's Hospital of Huai'an
For direct contact, visit the study record on ClinicalTrials.gov .